Literature DB >> 10482921

Triggering role of nitric oxide in the delayed protective effect of monophosphoryl lipid A in rat heart.

K György1, B Muller, A Vegh, A L Kleschyov, J C Stoclet.   

Abstract

1. The main objective of the present study was to further evaluate the role of nitric oxide (NO) in delayed cardiac protection against ischaemia-reperfusion injury induced by monophosphoryl lipid A (MLA). 2. For this purpose, rats were administered with either 0.5 or 2.5 mg kg(-1) MLA (i.p.). Eight or 24 h later, in vivo NO production in the heart was analysed by electron paramagnetic resonance (EPR) spin trapping technique. In parallel experiments, hearts were removed and perfused according to Langendorff. Functional ventricular parameters and incidence of ventricular fibrillation (VF) were determined after 30 min global ischaemic insult (37 degrees C) followed by 30 min reperfusion. Vascular reactivity of aortic rings was also assessed. 3. Hearts from rats pretreated with 2.5 mg kg(-1) MLA for 24 h (but not those from rats treated with 0.5 mg kg(-1) MLA for 8 and 24 h, or with 2.5 mg kg(-1) MLA for 8 h) exhibited preservation of ventricular function (LVDP, +/-dP/dtmax) and a reduced incidence of VF (25% vs 87.5% in vehicle control) during reperfusion. At the cardioprotective dose of 2.5 mg kg(-1) (for 8 or 24 h), MLA did not produce alterations of the contractile response of aortic rings to noradrenaline. 4. An increased formation of NO was detected in hearts removed from rats pretreated with 2.5 mg kg(-1) MLA for 8 h, but not in those from rats treated for 24 h (or with 0.5 mg kg(-1) MLA). 5. Pretreatment of the animals with the inhibitors of inducible NO-synthase, aminoguanidine (2x300 mg kg(-1)) or L-N6-(1-Iminoethyl)-lysine (L-NIL, 10 mg kg(-1)) abolished both MLA (2. 5 mg kg(-1))-induced rise of NO production (observed 8 h after MLA) and cardioprotection (observed 24 h after MLA). However MLA-induced cardioprotection was not attenuated when the hearts were perfused with aminoguanidine (150 microM) for 30 min before the ischaemic insult. 6. Altogether, the present data suggest that NO acts as a trigger rather then a direct mediator of the delayed cardioprotective effect of MLA in rat heart.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482921      PMCID: PMC1566171          DOI: 10.1038/sj.bjp.0702725

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  26 in total

1.  Selective inhibition of the inducible nitric oxide synthase by aminoguanidine.

Authors:  T P Misko; W M Moore; T P Kasten; G A Nickols; J A Corbett; R G Tilton; M L McDaniel; J R Williamson; M G Currie
Journal:  Eur J Pharmacol       Date:  1993-03-16       Impact factor: 4.432

2.  Beneficial modification of the endotoxin molecule.

Authors:  E Ribi
Journal:  J Biol Response Mod       Date:  1984

3.  Cardioprotective effects of monophosphoryl lipid A, a novel endotoxin analogue, in the dog.

Authors:  Z Yao; J A Auchampach; G M Pieper; G J Gross
Journal:  Cardiovasc Res       Date:  1993-05       Impact factor: 10.787

4.  Inhibition of nitric oxide formation by guanidines.

Authors:  K Hasan; B J Heesen; J A Corbett; M L McDaniel; K Chang; W Allison; B H Wolffenbuttel; J R Williamson; R G Tilton
Journal:  Eur J Pharmacol       Date:  1993-11-02       Impact factor: 4.432

5.  Aminoguanidine selectively inhibits inducible nitric oxide synthase.

Authors:  M J Griffiths; M Messent; R J MacAllister; T W Evans
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

6.  Effects of monophosphoryl lipid A on myocardial ischemia/reperfusion injury in dogs.

Authors:  Z Yao; J L Rasmussen; J L Hirt; D A Mei; G M Pieper; G J Gross
Journal:  J Cardiovasc Pharmacol       Date:  1993-10       Impact factor: 3.105

7.  Preconditioning of rat heart with monophosphoryl lipid A: a role for nitric oxide.

Authors:  A Tosaki; N Maulik; G T Elliott; I E Blasig; R M Engelman; D K Das
Journal:  J Pharmacol Exp Ther       Date:  1998-06       Impact factor: 4.030

8.  Pretreatment with a nontoxic derivative of endotoxin induces functional protection against cardiac ischemia/reperfusion injury.

Authors:  D W Nelson; J M Brown; A Banerjee; D D Bensard; K B Rogers; C R Locke-Winter; B O Anderson; A H Harken
Journal:  Surgery       Date:  1991-08       Impact factor: 3.982

9.  Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase.

Authors:  J R Connor; P T Manning; S L Settle; W M Moore; G M Jerome; R K Webber; F S Tjoeng; M G Currie
Journal:  Eur J Pharmacol       Date:  1995-01-24       Impact factor: 4.432

10.  L-N6-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase.

Authors:  W M Moore; R K Webber; G M Jerome; F S Tjoeng; T P Misko; M G Currie
Journal:  J Med Chem       Date:  1994-11-11       Impact factor: 7.446

View more
  3 in total

1.  Role of nitric oxide synthases in the infarct size-reducing effect conferred by heat stress in isolated rat hearts.

Authors:  C Arnaud; A Laubriet; M Joyeux; D Godin-Ribuot; L Rochette; P Demenge; C Ribuot
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

2.  Pharmacological delayed preconditioning against ischaemia-induced ventricular arrhythmias: effect of an adenosine A(1)-receptor agonist.

Authors:  R Tissier; R Souktani; O Parent de Curzon; N Lellouche; P Henry; J F Giudicelli; A Berdeaux; B Ghaleh
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

3.  Wine polyphenols induce hypotension, and decrease cardiac reactivity and infarct size in rats: involvement of nitric oxide.

Authors:  Hantamalala Ralay Ranaivo; Myriam Diebolt; Ramaroson Andriantsitohaina
Journal:  Br J Pharmacol       Date:  2004-05-24       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.